[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"growth\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:growth":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,60,88,113,152,177,216,238],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100632476","improving-artificial-intelligence-derived-algorithms-for-estimating-length-and-weight-in-neonates-and-infants-up-to-6-months-of-age-nest-100632476",false,"NCT07514182","Improving Artificial Intelligence-derived Algorithms for Estimating Length and Weight in NEonateS and infanTs up to 6 Months of Age (NEST)","Improving Artificial Intelligence-derived Algorithms for Estimating Length and Weight in NEonateS and infanTs up to 6 Months of Age","NEST","Inclusion Criteria:\n\n1. Infants up from birth up to 6 months of postnatal age (including neonates) who have been admitted to the NICU or SCN at the time of screening\n2. Parent(s) should be able to comprehend the content of the study and be willing for their child to undergo video and photo recording, and to allow access to their blood sampling results (haemoglobin) taken as part of standard clinical practice\n3. Written consent from parents and\u002For legally acceptable representative\n\nExclusion Criteria:\n\n1. Infants who were born with gestational age of less than 28 weeks of gestational age\n2. Infants who are intubated (i.e., endotracheal, nasotracheal intubation) at the time of screening\n3. The investigator considers for any reason that the participant would not be suitable for the study\n4. The participant has an existing medical condition that would prevent standardised measurement of length and\u002For head circumference e.g. structural abnormality of the lower limbs, orthopaedic conditions, hydrocephalus\n5. Employees and\u002For children\u002Ffamily members or relatives of employees of Danone Global Research \\& Innovation Center, Danone Asia Pacific Holdings Pte Ltd, or the participating site","ALL","0 Days","6 Months",{"count":21,"type":22},60,"ESTIMATED","2 Weeks","OBSERVATIONAL","The NEST study is a prospective, observational research study designed to collect clinical measurements and image data to develop and evaluate artificial intelligence (AI)-derived algorithms for estimating anthropometric parameters in neonates and young infants. The study focuses on infants from birth up to 6 months of age and aims to assess the accuracy of AI-based estimations of length, weight, and head circumference using photographs and\u002For video recordings captured during routine clinical care. These AI-derived measurements will be compared against standard clinical measurements obtained by trained healthcare professionals in neonatal and infant care settings.",[27,28,29],"Growth","Neonates","AI (Artificial Intelligence)",[28,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"Infants","Neonatal Growth","Infant Growth assessment","Anthropometric measurements","Infant length measurements","Infant weight measurement","Head Circumference","Artificial Intelligence","Image based assessment","Digital Health","Photographs and video recordings","Neonatal intensive care unit","Special Care nursery","Observational study","Proof of concept study","Growth monitoring","RECRUITING","2026-04-08",{"date":50,"type":51},"2026-04-13","ACTUAL",{"date":53,"type":51},"2026-03-26",{"date":55,"type":22},"2026-10",{"name":57,"class":58},"Danone Asia Pacific Holdings Pte, Ltd.","INDUSTRY",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":17,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100632424","extensively-hydrolyzed-formula-growth-monitioring-study-gms-100632424","NCT07513506","Extensively Hydrolyzed Formula Growth Monitioring Study (GMS)","GROWTH AND TOLERANCE OF A NEW INFANT FORMULA USING AN EXTENSIVELY HYDROLYZED CASEIN-BASED PROTEIN (eHCF)","Inclusion Criteria:\n\n* 10 to 14 days of age at randomization, inclusive (day of birth is considered Day 0)\n* Singleton birth\n* Gestational age of 37 weeks + 0 days to 41 weeks + 6 days, inclusive\n* Birth weight of 2500 g to 4200 g, inclusive\n* Birth weight appropriate for gestational age (AGA, defined as birth weight-for-age between 10th and 90th percentile, inclusive)\n* Exclusively receiving infant formula for at least 24 hours prior to randomization\n* Parent(s) or legal guardian(s) have full intention to exclusively feed their infant study formula through 126 days of age\n* Signed informed consent obtained from parent or legal guardian for infant's participation in the study\n* Signed authorization obtained from parent or legal guardian to use and\u002For disclose Protected Health Information for the infant from birth through the length of the study period\n* Parent or legal guardian agrees not to enroll the infant in another interventional clinical study while participating in this study\n* Decentralized participant's parent\u002Fcaregiver or legal guardian has access to reliable internet and technology for remote visits.\n* Decentralized participant's parent\u002Fcaregiver or legal guardian anticipates having a second adult available for all remote visits.\n\nExclusion Criteria:\n\n* History of underlying metabolic or chronic disease; congenital malformation; immunodeficiency, gastrointestinal condition, or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the infant to ingest food by mouth, the normal growth and development of the infant, or the evaluation of the infant\n* Evidence of feeding difficulties or history of formula intolerance, such as vomiting or poor intake at time of randomization\n* First degree relative (if known) history of cow's milk protein intolerance or allergy\n* Maternal history with known adverse effects on the fetus and\u002For newborn infant in the opinion of the investigator, such as, but not limited to diabetes, smoking, active tuberculosis, perinatal infection, or substance abuse\n* Weight at Visit 1 is \\\u003C98% of birth weight \\[weight at Visit 1÷ birth weight) x 100\\\u003C 98%\\]\n* Infants whose parent, legal guardian, or first-degree relative is an employee of MJN\u002FReckitt or an affiliated vendor (e.g., CRO, laboratory, or data management provider) involved in the clinical trial, and who is directly or indirectly engaged in the design, conduct, oversight, or analysis of the study; has access to confidential study information; or holds supervisory authority over personnel involved in the study.",true,"10 Days","14 Days",{"count":71,"type":22},214,"INTERVENTIONAL",[74],"NA","This is a research study to compare an investigational infant formula against a currently marketed infant formula. An investigational infant formula is one that has never been approved by the United States Food and Drug Administration (FDA).\n\nThe purpose of this research study is to evaluate the growth and tolerance of infants who consume a new (not yet available to buy) extensively hydrolyzed cow milk protein infant formula compared to an extensively hydrolyzed cow milk protein infant formula that is currently available to buy. The study will also look at the growth of your baby, how many poops your baby has, what the poops are like (for example, soft or hard), how much study formula your baby drinks, how well your baby handles the study formula (such as spit-up, fussiness, gas, colic, or changes in sleep), and any health problems that might come up during the study.",[27],"NOT_YET_RECRUITING","2026-03-30",{"date":80,"type":51},"2026-04-07",{"date":82,"type":22},"2026-04-03",{"date":84,"type":22},"2027-05-01",{"name":86,"class":58},"Mead Johnson Nutrition",12,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":72,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":59},"100624392","growth-and-feeding-tolerance-in-premature-infants-100624392","NCT07409038","Growth and Feeding Tolerance in Premature Infants","Effect of Early Human Milk Fortification Versus Delayed Fortification on Growth and Feeding Tolerance in Premature Infants: a Randomized Controlled Trial.","Inclusion Criteria:\n\n* Preterm infants born at 28-31+6 weeks' gestation and\u002For birth weight1000-1500g.\n* Exclusively receiving mother's own milk or donor human milk.\n* No major congenital anomalies, severe sepsis, or NEC at enrollment.\n* Parental\u002Fguardian consent\n\nExclusion Criteria:\n\n* Extremely pre-term infants\n* Infants with congenital gastrointestinal malformations or metabolic disorders.\n* Infants with confirmed necrotizing enterocolitis(NEC)Stage II\u002FIII or intestinal perforation before enrollment (as these cases indicate significant gastrointestinal morbidity that may interfere with feeding tolerance and growth assessment).\n* Infants whose parents decline participation.","28 Weeks","31 Weeks",{"count":98,"type":22},96,[74],"The main purpose of the study is to evaluate the effect of early human milk fortification versus delayed fortification on growth and feeding tolerance in premature infants.",[102,27],"Feeding Tolerance","2026-02-06",{"date":105,"type":51},"2026-02-13",{"date":107,"type":22},"2026-02-01",{"date":109,"type":22},"2026-07-01",{"name":111,"class":112},"Children's Hospital and Institute of Child Health, Multan","OTHER_GOV",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":67,"sex":17,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":125,"conditions":126,"keywords":133,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":59},"100517522","impact-of-diet-and-nutrition-on-growth-and-development-in-young-children-100517522","NCT06018636","Impact of Diet and Nutrition on Growth and Development in Young Children","Dietary Intake\u002FPatterns, Nutritional Status and Their Association With Growth and Development of Children From Remote, Agropastoral Communities of District Swat, Pakistan","DIGEST","Inclusion Criteria:\n\n* Households living in the area from the last two 2 years.\n* Households having infants or young children ≤ years.\n* Households planning to reside in the same area for the next 1 year.\n\nExclusion Criteria:\n\n* Children with any co-existent systemic diseases, confirmed from medical records.\n* Children on continuous medications for any medical issue.\n* Physically or mentally handicapped children","1 Day","24 Months",{"count":124,"type":22},832,"The association between nutrition in early life and its long-term health consequences has long been known. However, there is a scarcity of scientific evidence on how nutritional status affects child growth and development in remote, rural agro-pastoral communities with distinct dietary intake habits, geographical location, socio-economic status, and cultures.",[127,27,128,129,130,131,132],"Nutrition","Development","Stunting","Wasting","Obesity","Child Development",[134,135,27,136,137,138,139,140,141],"Nutritional status","Malnutrition","Cognitive Development","Anthropometry","Agropastoral","remote","rural","Urban","2026-01-06",{"date":144,"type":51},"2026-01-08",{"date":146,"type":51},"2023-06-28",{"date":148,"type":22},"2028-09-30",{"name":150,"class":151},"Khyber Medical University Peshawar","OTHER",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":67,"sex":17,"minAge":122,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":72,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100616944","oral-nutritional-supplementation-in-children-with-growth-concerns-100616944","NCT07312201","Oral Nutritional Supplementation in Children With Growth Concerns","Oral Nutritional Supplementation in Children With Growth Concerns: A Randomized, Controlled Single-blinded Study","Inclusion Criteria:\n\n* Child's parent(s) is of legal age of majority (18 years of age), must understand the informed consent form and other relevant study documents, and is willing and able to fulfill the requirements of the study protocol.\n* Evidence of a personally signed and dated informed consent document indicating that the child's parent(s) \u002F legally acceptable representative (LAR) has been informed of all pertinent aspects of the study.\n* Child was full-term at birth (i.e., ≥ 37 completed weeks of gestation with a birth weight of ≥ 2.5 kg and ≤ 4.5 kg).\n* Child is aged 24 - 41 months at inclusion.\n* Child is generally healthy (acute illnesses in a minor condition which are common in childhood such as viral or bacterial infections (e.g., conjunctivitis, otitis media, upper\u002Flower respiratory tract infection, gastroenteritis, hand foot \\& mouth disease) at time of enrolment is permitted).\n* Children whose parents, caregivers, or guardians show some concern about their child's dietary intakes and growth, such as child is too thin for his or her height, or child has experienced recent rapid weight loss or failure to gain weight or height and child has a z-score for weight-for-age or weight-for-height or both parameters ≤ -1SD as per WHO growth charts.\n* Child's parents agree to feed their child an oral nutritional supplement in addition to normal diet.\n* Child's parent(s) \u002F guardian can be contacted directly by telephone throughout the study.\n\nExclusion Criteria:\n\n* Child is currently breastfed or is consuming breast milk.\n* Child is currently consuming or consumed in the past month growing-up milk \u002F toddler formula. Growing-up milks \u002F toddler formulas are products specifically formulated for young children and provide key macro- and micro-nutrients.\n* Child is currently consuming or consumed in the past month oral nutrition supplement (ONS). The standard ONS formula has an energy density of at least 0.85 kcal\u002FmL, containing protein, carbohydrate and\u002For fat, as well as a wide range of micronutrients to supplement or use as the sole source of nutrition.\n* Child has known or suspected cows' milk protein intolerance \u002F allergy, lactose intolerance, galactosemia, soy intolerance \u002F allergy, fish oil intolerance \u002F allergy, or allergy or intolerance to any ingredient in the study product.\n* Child fed vegan, vegetarian, or vegetarian plus fish diets in which milk products are excluded.\n* Underlying medical illness that could affect growth or feeding, such as gastrointestinal \\[GI\\] disorders (such as celiac disease, short bowel syndrome, maldigestion\u002Fmalabsorption, significant GI malformations or surgery etc.); neurodevelopmental disability; chronic infections (such as tuberculosis or HIV infection); congenital disease or genetic disorders (such as congenital cardiac disease, Down syndrome, thalassemia); or other chronic illness that may impact growth or feeding according to the clinician opinion.\n* Child is unable to consume foods or ONS orally (e.g. dysphagia, anorexia, difficulty in swallowing due to acquired or congenital abnormalities that would hamper oral intake of the study product.)\n* Clinically significant nutritional deficiency requiring specific nutritional therapy other than the study product (for example tube feeding)\n* Child has acute illness including acute viral infection, respiratory tract infection etc. even in a minor condition at time of enrolment. A child presenting with an acute illness can be re-screened at least two weeks after the episode of illness has resolved.\n* Child has a z-score for weight-for-height or weight-for-age or height-for-age or any combination of these three parameters ≤ -3SD as per WHO growth charts.\n* Children currently receiving or having received prior to enrolment medication which are known to impact growth including systemic steroids, growth hormone and insulin\n* Child or child's parent(s) not willing and\u002For not able to comply with scheduled visits and\u002For have plans to relocate to a different geographical location from the study location during the study period.\n* Child of any investigational site staff member or Nestlé employee directly involved in the conduct of the trial.\n* Child is currently participating in or has participated in another clinical trial within 4 weeks prior to enrolment.","41 Months",{"count":161,"type":22},216,[74],"Multi-center, single-blinded, randomized, controlled study consisting of two arms, to investigate the impact of an oral nutritional supplement in combination with dietary counseling on growth in children with growth concerns as compared to children who receive dietary counselling alone",[27,165,166,167],"Toddlers","Attention","Cognitive Function","2025-12-16",{"date":170,"type":51},"2025-12-31",{"date":172,"type":22},"2026-09-30",{"date":174,"type":22},"2028-05-31",{"name":176,"class":58},"Société des Produits Nestlé (SPN)",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":184,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":72,"phases":187,"briefSummary":188,"conditions":189,"keywords":197,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":59},"100615440","the-effectiveness-of-the-twin-block-and-carriere-motion-appliances-in-post-pubertal-patients-and-an-evaluation-of-the-impact-of-class-ii-malocclusion-and-its-correction-on-oral-health-related-quality-of-life-100615440","NCT07292636","The Effectiveness of the Twin Block and Carriere Motion Appliances in Post-pubertal Patients and an Evaluation of the Impact of Class II Malocclusion and Its Correction on Oral Health-related Quality of Life","The Effectiveness of the Twin Block and Carriere Motion Appliances in Post-pubertal Patients and an Evaluation of the Impact of Class II Malocclusion and Its Correction on Oral Health-related Quality of Life: A Randomised Controlled Trial","Inclusion Criteria:\n\n1. males and females aged 14 ½ -16 years from the HSE waiting list,\n2. Cervical Vertebral Maturation (CVM) stage ≥5,\n3. a mild-moderate skeletal II pattern,\n4. normodivergent with average maxillomandibular planes angle (MMPA: 27±4 degrees),\n5. Class II division 1 incisor relationship,\n6. Class II molar relationship of ≥1\u002F2 unit bilaterally,\n7. overjet of ≥7 mm,\n8. ≤5mm of dental crowding in both arches and\n9. fluent English speaker.\n\nExclusion Criteria:\n\n1. high MMPA,\n2. low MMPA,\n3. have\u002Fhad cleft lip or palate or craniofacial syndrome,\n4. hypodontia,\n5. gross mandibular asymmetry,\n6. a medically diagnosed growth excess or deficiency,\n7. not dentally fit or\n8. had previously received orthodontic treatment.","14 Years",{"count":186,"type":22},88,[74],"The investigators of this clinical trial aim to:\n\n* Compare the effectiveness and efficiency of Clark's Twin Block Appliance (CTB) vs Carriere Motion Appliance (CMA) in correcting Class II malocclusion when used in post-pubertal older adolescents, in terms of skeletal and dental change.\n* Evaluate potential negative oral health-related quality of life (OHRQoL) impacts during the active treatment phase with either CTB or CMA in post-pubertal adolescents.\n* Investigate the impact of Class II malocclusion on oral health-related quality of life (OHRQoL) in post-pubertal adolescents.\n\nClass II division 1 malocclusion is a dental condition where the upper teeth protrude significantly over the lower teeth. It is a common type of malocclusion observed in orthodontic practice, accounting for approximately 20-25% globally. Correcting Class II malocclusion in growing patients using functional appliances and Class II correctors is relatively predictable.\n\nIn Ireland and the United Kingdom, the Clark's Twin Block (CTB) is the most commonly used functional appliance. The CTB consists of two components: one for the upper teeth and one for the lower teeth. These components are engineered to position the lower jaw forward, thereby promoting the desired dentoskeletal changes (moving the upper teeth back and lower forward). Another device used for Class II correction is the Carriere Motion Appliance (CMA). The CMA is gaining popularity as a treatment option for Class II malocclusion, inducing dental changes similar to those achieved with a CTB. However, uncertainty persists regarding the effectiveness of these appliances in older adolescents in the post-pubertal growth phase (aged approximately 14.5 years or above).\n\nAdditionally, although both CTB and CMA are effective in growing patients in correcting dental and skeletal discrepancies, they may influence daily activities, comfort, and psychological aspects, which often results in poor compliance. Poor adherence to orthodontic treatment, whether with fixed or removable appliances, can lead to higher rates of treatment failure.",[190,191,27,192,193,194,195,196],"CLASS II DIVISION 1 MALOCCLUSION","Class II Malocclusion","Overjet","Class II Buccal Segment Relationship","Class II Growth Modification","Distalization","Oral Health-Related Quality of Life",[191,192,198,199,200,201,202,203,204,205,206],"Class II Molar Relationship","Class II Canine Relationship","Functional Appliance","Class II Corrector","Growth Modification","Oral Health Related Quality of Life","Twin Block","Carriere Motion Appliance","RCT","2025-12-15",{"date":209,"type":51},"2025-12-18",{"date":211,"type":22},"2026-03",{"date":213,"type":22},"2029-09",{"name":215,"class":151},"Aslam Alkadhimi",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":72,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":237},"100481666","preterm-infants-fed-a-human-milk-fortifier-100481666","NCT05551975","Preterm Infants Fed a Human Milk Fortifier","Growth and Tolerance of Preterm Infants Fed an Experimental Human Milk Fortifier","Inclusion Criteria:\n\n* Birth weight between 700 g-1500 g.\n* ≤ 32 weeks and 0 days GA at birth.\n* Participant has been classified as appropriate for GA (AGA).\n* Enteral feeding of human milk must be initiated by 21 days of life (birth date is day of life 0)\n* Mother agrees to provide human milk as the exclusive feeding during the study period; use of donor milk is permitted if fortified with study fortifier and use of mother's own milk (when available) is prioritized.\n* Parent(s) agrees to allow infant to receive both human milk and study HMF.\n* Singleton or twin births only.\n* Infant's parent(s) or a LAR has voluntarily signed and dated an ICF, approved by an IRB\u002FIEC and provided HIPAA (or other applicable privacy regulation) authorization prior to any participation in the study.\n\nExclusion Criteria:\n\n* Enteral feeding of preterm infant formula or HMF for \\> 7 days.\n* Expected to be transferred to another facility within 30 days of randomization.\n* Serious congenital abnormalities or underlying disease that may affect growth and development.\n* 5-minute APGAR ≤ 4.\n* Receiving systemic steroids at time of randomization.\n* Receiving probiotics at time of randomization.\n* Grade Ill or IV PVH\u002FIVH.\n* Dependent on invasive ventilation at time of randomization.\n* Maternal incapacity.\n* Mother or infant is currently receiving treatment consistent with HIV therapy.\n* Documentation of maternal use of alcohol or marijuana during pregnancy that in the opinion of the physician is considered abuse.\n* Positive toxicology report for cocaine, opiates, or methamphetamine in mother or infant.\n* Infant has a history of major surgery (intra-thoracic or intra-abdominal procedures or other surgery requiring general anesthesia).\n* Asphyxia defined as progressive hypoxemia and hypercapnia with significant metabolic acidemia characterized by APGAR score \\\u003C3 at 10 minutes, seizures within the first 12 hours of life, or a cord blood gas \\\u003C 7.0 and seizures and\u002For severe tonic abnormalities in the first 12 hours of life.\n* Confirmed NEC (Bell's Stage II or III).\n* Confirmed current sepsis.\n* Infant has any other condition that, in the opinion of the investigator, precludes participation in the study.\n* Participation in another study that has not been approved as a concomitant study by AN.\n* Participant has an allergy or intolerance to any ingredient in study fortifier.",{"count":224,"type":22},321,[74],"This is a double-blind, randomized, multi-center, controlled, parallel study to evaluate the growth and tolerance of preterm infants fed human milk fortifier (HMF).",[27],"2024-06-26",{"date":230,"type":51},"2024-06-28",{"date":232,"type":22},"2024-09",{"date":234,"type":22},"2028-01",{"name":236,"class":58},"Abbott Nutrition",14,{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":246,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":72,"phases":250,"briefSummary":251,"conditions":252,"keywords":256,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":270},"100448262","enteral-feeding-in-infants-with-duct-dependant-lesions-100448262","NCT05117164","Enteral Feeding in Infants With Duct Dependant Lesions.","Effect of Standardised vs Local Preoperative Enteral Feeding Practice on the Incidence of NEC in Infants With Duct Dependent Lesions: a Randomised Control Trial.","CARDIOFEED","Inclusion criteria:\n\n1. Duct dependent congenital heart disease\n2. Term infants\n3. Parental\u002Flegal guardian consent\n\nExclusion criteria:\n\n1. Potential contradictions to early central feeding\n2. Feeding intolerance\n3. Hemodynamic instability\n4. Death\n5. \\> 50% formula based enteral feeding\n6. Birth weight less than 2500g","1 Minute","72 Hours",{"count":249,"type":22},384,[74],"This is a multicenter randomised controlled trial to assess whether standardised enteral feeding in newborns with duct dependenty congenital heart disease decreases the risk of necrotising enterocolitis (NEC). The investigators plan to include a total 384 infants. The study will be carried out in three level III hospitals in Poland. The primary end will be NEC and\u002For death. Secondary end points include weight gain, hospital length of stay, time required to reach full feeding.",[253,254,255,27],"Duct Dependent Lesions","Necrotising Enterocolitis","Death",[257,258,259,260],"congenital heart disease","nutrition","growth","newborn","2022-07-16",{"date":263,"type":51},"2022-07-20",{"date":265,"type":22},"2022-08-10",{"date":267,"type":22},"2026-12-31",{"name":269,"class":151},"Princess Anna Mazowiecka Hospital, Warsaw, Poland",2]